<DOC>
	<DOCNO>NCT00372567</DOCNO>
	<brief_summary>A phase IIIb study patient gastrointestinal stromal tumor progressive disease 400 mg imatinib . Patients randomly assign either sunitinib 37.5 mg daily imatinib 800 mg daily . This study find benefit potential side effect take sunitinib imatinib approximately one year .</brief_summary>
	<brief_title>Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description>The study prematurely discontinue July 27 , 2009 due poor recruitment operational futility result change clinical practice . There safety efficacy concern regard study decision terminate trial .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Patients gastrointestinal stromal tumor whose disease progress imatinib 400 mg daily . Current treatment chemotherapy imatinib . Current treatment dose imatinib 400 mg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>